Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

2.

Obesity linked to subsequent neoplasms in childhood cancer survivors

3.

Are ultramarathon runners really at increased risk of bowel cancer?

4.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

5.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot